Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA of anaerobic and microaerophilic organisms serves as the fundamental genetic blueprint required for the replication and survival of these specialized microbes. It is the primary therapeutic target for the nitroimidazole class of antibiotics, which exploit the unique low-redox potential environment of these organisms (StatPearls, NBK539728). Within the cell, the drug is reduced by enzymes such as pyruvate:ferredoxin oxidoreductase to form short-lived, highly reactive cytotoxic intermediates (PubChem, CID 4168). These intermediates, specifically nitroso-free radicals, interact directly with the DNA molecule, causing extensive strand breakage and destabilization of the double helix (PubMed, PMID 12111615). This interaction effectively halts DNA synthesis and causes rapid bacterial or protozoal cell death. Because the activation of these drugs requires the specific metabolic machinery of anaerobes, the DNA of aerobic host cells remains largely unaffected, providing a high degree of selective toxicity (Wikipedia, Metronidazole).
Nitroimidazole drugs act as prodrugs that are selectively reduced in anaerobic or microaerophilic environments by electron transport proteins like ferredoxin or flavodoxin (StatPearls, NBK539728). This reduction produces reactive nitroso-free radicals that interact with the DNA, causing strand breakage and destabilization of the helical structure, which inhibits nucleic acid synthesis and leads to cell death (PubChem, CID 4168; PubMed, PMID 12111615).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Deoxyribonucleic acid (DNA) of anaerobic and microaerophilic organisms (DNA).